Pursuant to Rule 9.20 of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, FINTEC GLOBAL BERHAD (“FINTEC” or “the Company”) wishes to announce that as at 1 March 2021, the aggregate value of quoted securities acquired by Asiabio Capital Sdn. Bhd. (“ABC”), a wholly-owned subsidiary of the Company, that is principally involved in the investment in marketable securities, that has not been announced for the preceding twelve (12) months has exceeded 5% of FINTEC’s latest audited consolidated net assets as at 31 March 2020. The details of the investment in the quoted securities are as follows:-
| |
|
RM
|
% of FINTEC's latest audited consolidated net assets
|
|
a.
|
Aggregate purchase consideration within the preceding twelve (12) months
|
19,518,820.15
|
5.11%
|
| |
|
|
|
b.
|
Aggregate sale consideration within the preceding twelve (12) months
|
-
|
-
|
| |
|
RM
|
|
c.
|
Investments in quoted securities as at 1 March 2021
|
|
| |
- Total Cost
|
213,310,110.76
|
| |
- Total Book Value
|
1,297,061,016.25
|
| |
- Total Market Value
|
1,155,891,451.76
|
| |
|
|
|
d.
|
Net Profit arising from the disposal of quoted securities by FINTEC Group during the current financial year ending 31 March 2021 (Sales proceeds less investment cost and incidental expenses)
|
-
|
The acquisition of the quoted securities as announced were made within the period from 31 December 2020 to 26 February 2021.
This announcement is dated 1 March 2021.